TY - JOUR
T1 - Cancer cachexia and anabolic interventions
T2 - A case report
AU - Dillon, Edgar
AU - Basra, Gurjot
AU - Horstman, Astrid M.
AU - Casperson, Shanon L.
AU - Randolph, Kathleen M.
AU - Durham, William
AU - Urban, Randall J.
AU - Diaz-Arrastia, Concepcion
AU - Levine, Lyuba
AU - Hatch, Sandra S.
AU - Willis, Maurice
AU - Richardson, Gwyn
AU - Sheffield-Moore, Melinda
PY - 2012/12
Y1 - 2012/12
N2 - Background: Standard-of-care (SOC) cancer treatments are primarily aimed at reducing size and progression of a tumor. There is a need for successful supplemental anabolic therapies to combat cancer cachexia in addition to these SOC treatment modalities. Anabolic interventions, including testosterone and amino acid supplements, may be beneficial in reducing and/or reversing muscle wasting in these patient populations. Methods: A 48-year-old Caucasian female with recurrent cervical cancer was scheduled to receive three 21-day cycles of cisplatin and topetecan chemotherapy. She qualified, consented, and enrolled into a blinded interventional pilot study where she received daily whey protein (10 g, three times per day with meals) and a weekly injection of testosterone enanthate (100 mg intramuscular) before and during the SOC chemotherapy treatment period. Body composition, serum inflammatory markers, mixed muscle protein synthesis and breakdown rates, physical function, fatigue, and quality of life were assessed before and after the intervention period. Results: Body composition, as assessed by an increase in body weight and lean body mass and reduction in fat mass; physical function; fatigue; and quality of life each improved across the entire intervention period despite general increases in inflammatory markers and no improvements in muscle protein turnover towards the end of the intervention. Conclusions: Concomitant treatment of oral amino acids and testosterone may be a viable therapeutic option for fighting cachexia and improving body composition and quality of life during chemotherapeutic treatment of recurrent cervical cancer. These positive outcomes may be attainable over time despite overall poor inflammatory status.
AB - Background: Standard-of-care (SOC) cancer treatments are primarily aimed at reducing size and progression of a tumor. There is a need for successful supplemental anabolic therapies to combat cancer cachexia in addition to these SOC treatment modalities. Anabolic interventions, including testosterone and amino acid supplements, may be beneficial in reducing and/or reversing muscle wasting in these patient populations. Methods: A 48-year-old Caucasian female with recurrent cervical cancer was scheduled to receive three 21-day cycles of cisplatin and topetecan chemotherapy. She qualified, consented, and enrolled into a blinded interventional pilot study where she received daily whey protein (10 g, three times per day with meals) and a weekly injection of testosterone enanthate (100 mg intramuscular) before and during the SOC chemotherapy treatment period. Body composition, serum inflammatory markers, mixed muscle protein synthesis and breakdown rates, physical function, fatigue, and quality of life were assessed before and after the intervention period. Results: Body composition, as assessed by an increase in body weight and lean body mass and reduction in fat mass; physical function; fatigue; and quality of life each improved across the entire intervention period despite general increases in inflammatory markers and no improvements in muscle protein turnover towards the end of the intervention. Conclusions: Concomitant treatment of oral amino acids and testosterone may be a viable therapeutic option for fighting cachexia and improving body composition and quality of life during chemotherapeutic treatment of recurrent cervical cancer. These positive outcomes may be attainable over time despite overall poor inflammatory status.
KW - Amino acids
KW - Cervical cancer
KW - Fatigue
KW - Lean body mass
KW - Quality of life
KW - Testosterone
UR - http://www.scopus.com/inward/record.url?scp=84880638546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880638546&partnerID=8YFLogxK
U2 - 10.1007/s13539-012-0066-6
DO - 10.1007/s13539-012-0066-6
M3 - Article
C2 - 22585408
AN - SCOPUS:84880638546
SN - 2190-5991
VL - 3
SP - 253
EP - 263
JO - Journal of Cachexia, Sarcopenia and Muscle
JF - Journal of Cachexia, Sarcopenia and Muscle
IS - 4
ER -